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ABSTRACT 
Objective: Observational studies point to an inverse correlation between LDL cholesterol levels 
and risk of intracerebral hemorrhage (ICH), but it remains unclear whether this association is 





Methods: We constructed one polygenic risk score (PRS) per lipid trait (total cholesterol, LDL, 
HDL and triglycerides) using independent genome-wide significant SNPs for each trait. We used 
data from 316,428 individuals enrolled in the UK Biobank to estimate the effect of each PRS on 
its corresponding trait, and data from 1,286 ICH cases and 1,261 matched controls to estimate 
the effect of each PRS on ICH risk. We used these estimates to conduct Mendelian 
Randomization analyses.  
Results: We identified 410, 339, 393, and 317 lipid-related SNPs for total cholesterol, LDL, HDL 
and triglycerides, respectively. All four PRSs were strongly associated with their corresponding 
trait (all p<1x10-100). While  one standard deviation increase in the PRSs for total cholesterol (OR 
0.92, 95%CI 0.85-0.99; p=0.03) and LDL cholesterol (OR 0.88; 95%CI, 0.81-0.95; p=0.002) were 
inversely associated with ICH risk, no significant associations were found for HDL and 
triglycerides (both p>0.05). Mendelian Randomization analyses indicated that 1 mmol/L (38.67 
mg/dL) increase of genetically-instrumented total and LDL cholesterol were associated with 23% 
(OR 0.77; 95%CI 0.65-0.98; p=0.03) and 41% lower risks of ICH (OR 0.59; 95%CI 0.42-0.82; 
p=0.002), respectively.  
 
Interpretation: Genetically elevated LDL levels were associated with lower risk of ICH, providing 
support for a potential causal role of LDL cholesterol in ICH.  
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INTRODUCTION 
Novel therapies are needed for spontaneous, non-traumatic intracerebral hemorrhage (ICH), a 
disease responsible for 50% of stroke-related deaths and disability with no proven acute 
treatments.1 Several complementary lines of evidence highlight the importance of lipid 
metabolism as a promising pathophysiological pathway for risk prediction and therapeutic 
strategies.  The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial 
reported that statin treatment in surviving adults with a first ischemic stroke reduced the risk of 
recurrent ischemic stroke but increased the risk of ICH.2 However, this trial  could not exclude 
possible pleiotropic effects of statins, whereby the effects on ICH may be independent of the 
effects of statins on lipids.3 In addition, clinical trials investigating statins as the primary 
cardiovascular disease prevention strategy have yielded inconsistent results for ICH risk.4–6  
 
Results from several observational studies evaluating data from thousands of ICH cases also 
reported inverse associations between lipid levels and ICH risk. The Genetic and Environmental 
Risk Factors for Hemorrhagic Stroke (GERFHS) Study reported a one third lower ICH risk among 
study participants with a past medical history of hypercholesterolemia.7 Other observational 
studies reported that higher low-density lipoprotein cholesterol (LDL-C) levels were correlated 
with ICH severity and 3-month clinical outcome.8 While promising, these studies are limited by 
the observational nature of the underlying design, which preclude the possibility of establishing 
causality.  
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Population genetics provides powerful tools to overcome such limitations in causal inference. 
Genetic variants known to associate with lipid levels can be used as instruments to evaluate the 
causal relationship between different lipid fractions and risk of ICH.9 These genetic variants are 
randomly distributed during meiosis and are ought to be exempt from confounding by 
environmental exposures.9–11 A recent report from the China Kadoorie Biobank involving several 
thousand ICH cases demonstrated concordant effects estimates between the observational and 
genetic analyses for LDL-C and ICH risk in Chinese adults, thereby providing strong support for 
the causal relevance for this association in this ethnic group. However, in contrast with highly 
significant inverse observational associations of directly-measured LDL-C and ICH risk, the 
associations of genetically-instrumented LDL-C and ICH risk were not statistically significant in 
this study.12 
 
To overcome the limitations of previous randomized trials, observational studies and genetic 
analyses, we conducted a multistage genetic association study that combined polygenic risk 
score13 (PRS) and Mendelian randomization9 (MR) analyses to test the hypothesis that 
genetically-elevated lipid levels are associated with a lower risk of ICH. We separately evaluated 
the associations of genetically-instrumented differences in total cholesterol (TC), low-density 
lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides. 
Because of the known differences in underlying biology according to the location of ICH within 
the brain, we conducted stratified analyses based on hemorrhage location.14  
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We conducted a three-stage genetic study in participants from European ancestry. All study 
stages utilized publicly available individual-level data accessible through the National Institute of 
Health database of Genotypes and Phenotypes and UK Biobank. All studies had approval from 
the local institutional review board or ethics committee at each participating institution. Informed 
consent was obtained from all study participants or their legally authorized representatives, or 
consent was waived via protocol-specific allowance. All study participants had available genome-
wide genotyping data, allowing the implementation of principal component analysis to confirm 
ancestry and account for population stratification. In stage 1, we constructed four PRSs for TC, 
LCL-C, HDL-C and triglycerides using genetic variants known to associate with each of these 
traits in previous studies.15–17 We estimated the effect of each PRS on its corresponding lipid trait 
using data from the UK Biobank. In stage 2, we conducted an individual participant data meta-
analysis of genetic studies of ICH to evaluate the association between the four PRSs created in 
stage 1 and risk of ICH. This stage included individual-level data from three case-control genetic 
studies: the Genetics of Cerebral Hemorrhage on Anticoagulation (GOCHA) Study,18 International 
Stroke Genetics Consortium ICH Study (ISGC-ICH),19 and the Genetic and Environmental Risk 
Factors for Hemorrhagic Stroke (GERFHS) Study.7 In stage 3, we combined the effect estimates 
from stage 1 (associations between each PRS and its corresponding lipid fraction) and stage 2 
(associations between each PRS and ICH risk) to conduct MR analyses of genetically-
instrumented lipid levels and ICH risk.  
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Blood lipids in the UK Biobank 
Stage 1 utilized data from the UK Biobank, a prospective population-based cohort study that 
recruited 500,000 community-dwelling individuals aged 40 to 69 years between 2006 and 2010 
from across the United Kingdom. Study participants undergone multiple baseline physical 
measures, provided blood, urine and saliva samples for different analysis, provided detailed 
information about themselves, and agreed to have their health followed.20 We used recently 
released values for lipid traits which were measured using a Beckman Colter AU5800 clinical 
chemistry analyzer. Analyzer performance was verified continually throughout the project. 
 
Ascertainment of ICH cases and ICH-free controls 
ICH cases included in Stage 2 were defined as new and acute (<24hours) neurological deficits 
with consistent findings in neuroimaging. Cases were aged >55 years in GOCHA, and >18 years 
in GERFHS and the ISGC-ICH. Patients were excluded if they were taking anticoagulants 
(antiaggregants were permitted) or had head trauma, hemorrhagic conversion of an ischemic 
stroke, intracerebral tumor, intracerebral vascular malformation, vasculitis, or any other cause of 
secondary ICH. Controls included in Stage 2 were ICH-free individuals enrolled at the same study 
sites as cases and followed the same age and ethnicity criteria. Controls were sampled by random 
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For ICH cases included in Stage 2, stroke neurologists or neuroradiologists at each participating 
site confirmed the diagnosis and, following the known differences in underlying biology, classified 
each case as lobar or nonlobar according to location.21 ICH originating in the corticosubcortical 
junction was defined as lobar, whereas ICH selectively involving the thalamus, internal capsule, 
basal ganglia, brainstem, or cerebellum was defined as nonlobar. 
 
Genetic data 
Study participants were genotyped using the UK Biobank Axiom Array (UK Biobank Study), 
Illumina HumanHap610-Quad (GOCHA and ISGC-ICH), and Affymetrix 6.0 (GERFHS). Standard 
quality control procedures22 were implemented separately for each participating study. SNPs with 
palindromic alleles (A/T or C/G), a genotype call rate <95%, significant difference in missingness 
between cases and controls (p<0.05), deviation from Hardy-Weinberg Equilibrium (p<1x10-6), or 
minor allele frequency (MAF) <1% were removed. Individuals with a genotype call rate <95%, 
inconsistency between self-reported and genotyped sex, an inferred first or second degree 
relative in the sample, and a genome-wide heterozygosity F-statistic greater than five times the 
standard deviation were filtered out from the analysis. Principal component analysis was 
implemented to account for population structure.23 After quality control and principal component 
analyses, genetic data were prephased and imputed to 1000 Genomes integrated reference 
panels (Phase 3 integrated variant set release in NCBI build 37).24 Post-imputation filters included 
MAF <1%, an information score <0.7, and missing estimates in one or more studies.  
 
Statistical analyses 
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We present discrete variables as counts (percentage) and continuous variables as mean 
(standard deviation [SD]) or median (interquartile range [IQR]), as appropriate.  
Stage 1. Derivation of lipid-related PRSs. We used PRSs to model each individual’s genetic 
load of lipid-related risk alleles. To build these PRSs, we queried the GWAS Catalog and reviewed 
published genome-wide association studies of lipids.15–17 Following similar recent analyses, we 
selected independent (r2<0.3) and common (MAF>5%) single nucleotide polymorphisms (SNPs) 
associated with at least one lipid trait at p<5x10-8.15 All selected SNPs were aligned to the 
GRCh37 assembly of the human genome and, for each SNP, the allele associated with an 
increase in lipid levels was identified and utilized as the tested allele in downstream analyses. 
The epsilon variants within APOE were not included in these PRSs, as they are not captured by 
commercially available genotyping arrays and there is a plausible alternative pathway via cerebral 
amyloid angiopathy that could mediate its association with ICH.25 The PRS for each individual is 
the sum of the product of the risk allele counts for each locus multiplied by the allele’s reported 
effect on the corresponding lipid level. To assure common directionality of effects, the allele 
associated with higher lipid levels was selected as the effect allele during scoring. One PRS per 
lipid trait was generated (TC, LDL-C, HDL-C and triglycerides). All four PRSs were standardized 
(by subtracting the mean and dividing by the SD) and entered as continuous predictors into 
regression models. With this approach, the beta for the PRS can be interpreted as the change in 
ICH risk per 1 SD increase of the PRS. The association between each PRS and its corresponding 
lipid trait was evaluated using linear regression, adjusting for age, sex, and principal components 
1 to 4. The primary analysis was restricted to unrelated study participants of genetically-
determined European ancestry who were not taking lipid-lowering medications. In secondary 
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analyses, we followed a less restrictive approach and included all study participants of self-
reported European ancestry. 
Stage 2. Association between each PRS and ICH risk. We evaluated the association between 
each PRS and risk of ICH via logistic regression adjusting for age, sex and principal components 
1 to 4. Analyses were completed separately in each genetic study and pooled in meta-analysis 
using fixed-effects (primary analysis) and random effects (secondary analysis) approaches with 
evaluation of heterogeneity via Cochrane’s Q (with corresponding p) and I2. In sensitivity 
analyses, we excluded genetic variants within CETP, a locus that powerfully modifies lipid levels 
previously shown to be associated with ICH risk. To account for recognized differences in 
underlying causative ICH mechanism by location within the brain, lipid traits with significant 
associations were taken forward to stratified analyses based on hemorrhage location (lobar or 
nonlobar).  
Stage 3. Mendelian randomization analyses. The causal relationship between genetically-
determined lipid levels and ICH risk was evaluated via MR analyses using each PRS as an 
instrument. The primary MR analysis utilized the ratio method combining the point estimates and 
standards errors from Stage 1 (denominator) and Stage 2 (numerator). In secondary analyses, 
we implemented other MR methods usually used with summary level data, including inverse-
variance weighted, weighted median, MR-Egger, and Mendelian Randomization Pleiotropy 
Residual Sum and Outlier (MR-PRESSO) analyses. To confirm the validity of our results, we 
implemented MR analyses of genetically-instrumented cholesterol levels and risk of ischemic 
stroke using estimates for lipids levels from the UK Biobank and estimates for ischemic stroke 
This article is protected by copyright. All rights reserved.
 
 
- 13 - 
risk from the MEGASTROKE26 consortium; these results were compared with previously reported 
MR studies for the same analysis.  
Software. We used the GWAS Catalog to identify genetic variants related to lipid levels, PLINK 
for quality control procedures and generation of PRSs,27 EIGENSTRAT for principal component 
analysis,28 SHAPEIT for genotype prephasing,29 IMPUTE2 for imputation,30 and Rstudio 
(Version1.1.453) for association testing, meta-analysis, and MR analysis.31 
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RESULTS. Selected population characteristics are presented in Table 1. 
 
Stage 1: Derivation of cholesterol-related PRSs 
We identified 1,459 common (MAF >5%) genetic variants reported by prior studies as strongly 
associated with one or more of the lipid traits of interest. These common variants included 410 
SNPs for TC, 339 for LDL-C, 393 for HDL-C and 317 for triglycerides (Supplementary Tables 1-
4). We built four different PRSs, one for each lipid trait, and evaluated their associations with their 
corresponding trait in the UK Biobank. All four PRSs showed highly significant associations with 
their corresponding lipid trait, both in the primary analysis considering 316,428 (mean age 68 [SD 
8], 170,871 females [54%]) unrelated individuals of European ancestry not on lipid-lowering 
medications (all p<1x10-100), and in the secondary analysis not applying any exclusion criteria (all 
p<1x10-100; Table 2). 
 
Stage 2: Association between each PRS and ICH risk 
 A total of 1,286 ICH cases (mean age 71 [SD 13], 593 females [46%]) and 1,261 ICH-free controls 
(mean age 68 [SD 14], 613 females [49%]) from the GOCHA, ISGC ICH, and GERFHS studies 
were included in association testing (Table 1). For TC, each additional SD increase of the 
corresponding PRS was associated with an 8% lower ICH risk (OR 0.92, 95%CI 0.85-0.99; 
p=0.03). When evaluating specific lipid fractions, we found that each additional SD increase of 
the LDL-C- based PRS was associated with a 12% lower risk of ICH (OR 0.88, 95%CI 0.81-0.95; 
p=0.002) (Table 3). Similar results were obtained when utilizing random-effects meta-analyses. 
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These associations remained significant after removing CETP (Table 4). We did not find 
significant associations for the PRSs based on HDL-C or triglycerides (both p >0.05).  
 
Stage 3: Mendelian randomization analysis 
The primary MR analysis implemented the ratio method utilizing the effect estimates obtained in 
Stages 1 and 2. As shown in Table 5, each 1 mmol/L (or 38.67 mg/dL) increase of genetically-
instrumented TC was associated with a 23% reduction of ICH risk (OR 0.77, 95%CI 0.60-0.98; 
p=0.03), whereas a 1 mmol/L (or 38.67 mg/dL) increase of genetically-instrumented LDL-C was 
associated with a 41% reduction in this risk (OR 0.59, 95%CI 0.42-0.82; p=0.002). These results 
remained unaltered when the effect of each PRS on its corresponding lipid trait was estimated 
without excluding any individuals from the UK Biobank (data not shown). Secondary analyses 
utilizing an r2<0.1 yielded comparable results for LDL-C (OR 0.62, 95%CI 0.41-0.94; p=0.02) and 
confirmed the direction of effect for TC without reaching statistical significance (OR 0.94, 95%CI 
0.87-1.02; p=0.17). Secondary analyses utilizing other MR methods confirmed the direction of 
effect, although not all yielded statistical significance (Table 5). There was no indication of 
pleiotropy for either TC or LDL-C (MR‐egger intercepts and MR-PRESSO global test p>0.05). MR 
analyses for LDL-C and risk of ischemic stroke utilizing the estimates for LDL-C from the UK 
Biobank yielded similar results to those reported by prior publications based on lipid estimates 
from the Global Lipid Genetics Consortium (Table 6).  
 
Stratification based on location of the ICH within the brain 
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A total of 1,243 ICH cases (96%) had available information about the location of the hematoma 
within the brain. Of these, 539 (43%) had lobar ICH and 704 (56%) had nonlobar ICH. Location-
specific analyses indicated that the association between the LDL-C PRS and ICH risk remained 
significant for both lobar (OR 0.81, 95%CI 0.73-0.89; p<0.001) and nonlobar ICH (OR 0.90, 
95%CI 0.82-0.99; p=0.04 - Table 7), whereas the association between ICH risk and the TC PRS 
was significant for lobar (OR 0.89, 95%CI 0.80 - 0.99; p=0.03) but not nonlobar bleeds (OR 0.94, 
95%CI 0.85-1.08; p=0.20). Mendelian randomization analyses implementing the ratio method 
using these location-specific estimates indicated that genetically-elevated LDL-C was associated 
with a decreased risk of ICH for both lobar (OR 0.41, 95%CI 0.27-0.64; p<0.001) and nonlobar 
ICH (OR 0.66, 95%CI 0.44-0.97; p=0.04), whereas genetically elevated TC was associated with 
a decreased risk of lobar (OR 0.70,  95%CI 0.51-0.96; p=0.03) but not nonlobar ICH (OR 0.73, 
95%CI 0.62-1.11;p=0.20).   
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DISCUSSION 
We report the results of a multi-stage genetic association study that evaluated whether 
genetically-instrumented levels of different lipid traits influence the risk of spontaneous ICH. We 
constructed four PRSs to model the aggregate genetic load of risk alleles for TC, LDL-C, HDL-C 
and triglycerides; assessed for association between each PRS and its corresponding lipid trait; 
assessed for association between each PRS and ICH risk; and utilized the estimates obtained in 
prior steps to conduct MR analyses. We found that all four PRSs were robustly associated with 
their corresponding lipid trait and that the PRSs for TC and LDL-C were inversely associated with 
ICH risk. Analyses stratified by location indicated that these associations remained significant for 
both lobar and nonlobar ICH, with stronger associations for lobar bleeds. Of note, the genetically-
instrumented HDL-C and triglycerides levels were not associated with ICH risk. 
 
Previous studies provided promising, but inconclusive, evidence on the relevance of LDL-C for 
risk of ICH. The evidence from randomized control trials of statins is inconsistent. The SPARCL 
trial, a study focused on the utilization of statins for secondary prevention after a first stroke or 
transient ischemic attack, found an unexpected increment in ICH risk as a side effect.2 However, 
large meta-analyses of statin trials yielded conflicting conclusions for this question, with some 
finding similar associations5,12 and others finding nulls results.4 This inconsistencies may be driven 
by a lack of statistical power, as ICH is a rare event and statin trials, while large, do not accrue 
the necessary number of events to appropriately evaluate this relationship. From an observational 
perspective, the Genetic and Environmental Risk Factors for Hemorrhagic Stroke Study reported 
a reduction in ICH risk among study participants with a history of hypercholesterolemia.7 In terms 
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of genetic evidence, a candidate gene study focused on the powerful lipid regulatory gene CETP 
found an association between variants at this locus and ICH risk 32 While promising, each of these 
pieces of evidence has an important limitation: the inconsistency of results observed in clinical 
trials of statin treatment, the inability to draw causal conclusions in observational studies, and the 
and the single-locus design nature of the CETP study.  
 
The present study provides important additional evidence to support a causal role of LDL-C 
cholesterol in risk of ICH. Genetic variants known to be associated with lipid levels can be used 
as instruments to evaluate a causal relationship between different lipid fractions and ICH risk.33 
We deployed two specific strategies to maximize the accuracy and power of this analytical 
strategy. First, all analytical steps used individual level phenotypic and genotypic data, permitting 
the utilization of rigorous quality control procedures and the implementation of sensitivity analyses 
to evaluate whether results were robust to different modeling strategies. Second, we estimated 
the effect of our instruments, the four lipid-related PRSs, on newly released data on lipid fractions 
from the UK Biobank. The sample size of this study (400,000+ study participants) maximizes the 
discovery power of the MR analysis by improving the precision of the estimates.  
 
Beyond providing support for a causal role of lipid metabolism in ICH in Europeans, our results 
also support a specific role of LDL-C as the operative lipid trait mediating the observed inverse 
associations. Previous studies in Asians, who have lower LDL-C levels than Western populations, 
reported that this lipid fraction is the likely mediator underlying the inverse association between 
TC and ICH risk. A nested case-control study within the prospective China Kadoorie Biobank 
This article is protected by copyright. All rights reserved.
 
 
- 19 - 
involving ~5,000 ICH cases reported that elevated levels of LDL-C  were inversely associated 
with risk of ICH.12 Mendelian randomization analyses in this study yielded concordant effect 
estimates, although these were not statistically significant, possibly due to the lower number of 
SNPs utilized to build the instrument (59 variants) and the European origin of the populations 
where these lipid-related SNPs  had originally been identified. Our results confirm the role of LDL-
C as the mediating lipid fraction and provide evidence supporting its role in persons of European 
ancestry. We acknowledge that, while concordant in the direction of effect, the point estimates for 
the MR analysis of LDL-C and ICH risk yielded by the present study (OR 0.59, 95%CI 0.42-0.82) 
are significantly more extreme than those reported in the China Kadoorie Biobank (OR 0.89, 
95%CI 0.62-1.16). The discrepant results could reflect the lower mean age at ICH onset and lower 
mean LDL-C levels in Chinese compared with Europeans or between-population differences in 
the distribution of LDL-C which could have biased such comparisons. While the overlap in 
confidence intervals between European and Chinese studies indicate that differences in the 
estimates between studies are not statistically significant, precise estimates of effects of LDL-C 
on ICH risk will require additional analyses in further studies involving larger numbers of ICH 
cases.  
 
The independent replication of our findings constitutes an important next step to consolidate lipid 
metabolism as an actionable biological target in ICH. This follow-up studies will be greatly 
facilitated by increasingly available data from large biobanks and multi-purpose repositories like 
dbGaP34 and the European Genome-phenome Archive (EGA).35 Another important future 
direction involves the clarification of the pathophysiology underlying the observed association. 
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Histopathological evidence in humans suggests that lower cholesterol concentrations may 
increase the frailty and permeability of brain vessel walls, triggering arterionecrosis, 
microaneurysm formation and, ultimately, ICH.36,37 Because our findings point to an effect that is 
present for both lobar and deep hemorrhages, it is possible that low lipid levels could work as an 
effect modifier of the risk conveyed by the underlying small vessel disease responsible for the 
bleed.  
 
The results of this study prompt questions about the risk-benefit ratio of lowering LDL cholesterol 
for risk of different stroke types. The China Kadoorie Biobank demonstrated equal and opposite 
proportional differences in risk of ischemic stroke and ICH for equivalent differences in LDL-C 
cholesterol. Because the absolute number of ischemic stroke cases exceeded those of ICH by 4-
fold, any beneficial effects of lowering LDL-C on ischemic stroke were likely to outweigh risks of 
ICH. In light of this evidence, it is reasonable to use extreme caution when evaluating possible 
applications of these results to clinical decision-making.  
 
An important limitation of our study was the inability to evaluate the effect of other lipid fractions. 
Alongside the vast majority of related studies,  we evaluated TC, LDL-C, HDL-C and triglycerides, 
the four lipid traits routinely used in clinical practice, and did not account for several other 
cardiovascular risk-stratifying lipid fractions, such as apolipoprotein levels.38–40 A second 
important limitation is the absence of an independent dataset to replicate the association analysis 
between the lipid-related PRS and  ICH risk. The relatively low incidence of ICH in Western 
populations limits the amount of appropriately ascertained cases within available genetic and 
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location information. Nevertheless, the estimates observed in three different genetic studies of 
ICH were consistent with each other.  In addition, because this study was not intended at risk loci 
discovery, it could be argued that independent replication for this specific analysis is not strictly 
needed. Finally, the limited available data on medical history and use of medication in ICH cases 
precluded any detailed analysis of possible interactions or confounding effects by these variables.  
 
SUMMARY 
In conclusion, we report an inverse association between the genetic load of risk alleles for total 
and LDL-C and risk of ICH in persons of European ancestry. We also found that genetically-
instrumented higher total and LDL-C  were inversely associated with this same risk. Similar 
associations were observed for both lobar and nonlobar ICH. Our results support a potential 
causal role of LDL-C in risk of primary, non-traumatic ICH. ACKNOWLEDGEMENTS 
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Acronyms: UK: United Kingdom; GOCHA: Genetics of Cerebral Hemorrhage with Anticoagulation; ISGC: International Stroke 
Genetics Consortium; GERFHS: Genetic and Environmental Risk Factors for Hemorrhagic Stroke; ICH: intracerebral hemorrhage; 
PRS: polygenic risk score; SNPs (single nucleotide polymorphisms); SD: standard deviation. 
 
Table 1. Studies included in this analysis. 
Characteristic UK Biobank GOCHA ISGC ICH Study GERFHS 
Analytical stage Association Cholesterol level ~ PRS 
Association 
ICH Risk ~ PRS 
Association 
ICH Risk ~ PRS 
Association 
ICH Risk ~ PRS 
Study design Cohort Case / Control Case / Control Case / Control 
Study participants 316,428 277 / 248 563 / 523 446 / 490 
Age, mean (SD) 68 (8) 73 (10) / 72 (8) 71 (14) / 66 (16) 70 (14) / 68 (13) 
Female sex n, % 170,871 (54) 130 (47) / 123 (50) 252 (45) / 255 (49) 211 (47) / 235 (48) 




HumanHap550 Affymetrix 6.0 
Genotyped SNPs 820,967 527,508 527,508 580,491 
Imputed SNPs 73,355,667 7,965,700 7,965,700 7,967,430 
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Table 2. Association results for 4 PRS with their corresponding trait in the UK Biobank. 
Lipid Trait PRS Independent SNPS in PRS 
UK Biobank  
Effective  
sample size 
Mean increase in  
cholesterol trait per 





      
Total Cholesterol 410 316,428 0.33 mmol/L (12.76 mg/dL) 0.0018 9.33% <1x10-100 
LDL Cholesterol 339 315,841 0.24 mmol/L (9.28 mg/dL) 0.0014 8.38% <1x10-100 
HDL Cholesterol 393 289,349 0.11 mmol/L (4.25 mg/dL) 0.0006 8.17% <1x10-100 
Triglycerides 317 316,174 0.22 mmol/L (19.49 mg/dL) 0.0017 4.8% <1x10-100 
      
Total Cholesterol 410 437,676 0.26 mmol/L (10.05 mg/dL) 0.0017 5.21% <1x10-100 
LDL Cholesterol 339 436,867 0.19 mmol/L (7.35 mg/dL) 0.0013 4.72% <1x10-100 
HDL Cholesterol 393 400,579 0.11 mmol/L (4.25 mg/dL) 0.0005 8.04% <1x10-100 
Triglycerides 317 437,331 0.23 mmol/L (20.37 mg/dL) 0.0015 5% <1x10-100 
 
Acronyms: PRS: polygenic risk score; UK: United Kingdom; SNP: single nucleotide polymorphism; LDL: low-density lipoprotein; HDL: High-density lipoprotein. Conversion 
of mmol/L to mg/dL: for TC, LDL and HDL 1 mmol/L = 38.67 mg/dL; for triglycerides, 1 mmol/L = 88.57 mg/dL. 
 
* The primary analysis was restricted to unrelated study participant of genetically-determined European ancestry who were not taking lipid-lowering medications. 
 
** The secondary analysis included all study participants of self-reported European ancestry without any other filters. 
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Acronyms: ICH: intracerebral hemorrhage; PRS (polygenic risk score); LDL: low-density lipoprotein; HDL: high-density lipoprotein; CI: 
confidence interval; GOCHA: Genetics of Cerebral Hemorrhage with Anticoagulation; ISGC: International Stroke Genetics Consortium; 
GERFHS: Genetic and Environmental Risk Factors for Hemorrhagic Stroke; FE: Fixed-Effects. RE: Random effects. Het-p: heterogeneity-
p for the metanalysis. 
Table 3: Study-specific and metanalysis of logistic regression results modeling ICH risk as a function of different PRS.  
Study 
Total Cholesterol LDL Cholesterol HDL Cholesterol Triglycerides 
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P  
GOCHA 0.95 (0.80 - 1.14) 0.59 0.93 (0.78 - 1.11) 0.41 1.12 (0.94 - 1.34) 0.20 0.95 (0.80 - 1.14) 0.59 
ISGC ICH  0.93 (0.82 - 1.05) 0.24 0.88 (0.77 - 0.99) 0.04 1.15 (1.01 - 1.30) 0.03 1.01 (0.89 - 1.14) 0.84 
GERFHS 0.88 (0.77 - 1.01) 0.07 0.85 (0.75 - 0.97) 0.02 0.99 (0.86 - 1.12) 0.84 1.19 (1.04 - 1.36) 0.009 
Fixed effects  
Meta-analysis 0.92 (0.85 - 0.99) 
0.03  
 0.88 (0.81 - 0.95) 
0.002 
 1.10 (1.00 - 1.21) 
0.06  




Meta-analysis 0.92 (0.84 - 0.99) 0.03 0.88 (0.81 - 0.95) 0.002 1.08 (0.98 - 1.19) 0.13 1.05 (0.93 – 1.20) 0.42 
Heterogeneity I2=0% 0.77 I2=0%  0.75 I2=32% 0.23 I2=60% 0.08 
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Table 4: Metanalysis of logistic regression results modeling ICH risk as a function of different PRS, excluding 
CETP variants. 
 
Lipid PRS OR (95% CI) P 
Total Cholesterol 0.91 (0·84 - 0·99) 0.03 
LDL Cholesterol 0.88 (0·81 - 0·96) 0.003 
HDL Cholesterol 1.12 (0·99 - 1·21) 0.08 
Triglycerides 1.11 (0·98 - 1·23) 0.12 
 
Acronyms: ICH: intracerebral hemorrhage; PRS (polygenic risk score); CI: confidence interval; LDL: low-
density lipoprotein; HDL: high-density lipoprotein. 
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Table 5: Mendelian randomization analysis of genetically instrumented lipid levels and risk of ICH. 
 
 
Acronyms: ICH: intracerebral hemorrhage; LDL: low-density lipoprotein; OR: odds ratio; CI: confidence interval; SNPs: single 






Total Cholesterol LDL Cholesterol 
OR (95%CI) P OR (95%CI) P 
Ratio method Polygenic risk score 
using on individual level data 0.77 (0.6 - 0.98) 0.03 0.59 (0.42 - 0.82) 0.002 
IVW Multiple SNPs 
using summary level data 0.84 (0.72 - 0.99) 0.04 0.65 (0.52 - 0.82) <0.001 
Weighted median Multiple SNPs 








using summary level data 1.00 (0.99 - 1.01) 0.81 1.00 (0.98 - 1.01) 0.59 
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Table 6. Sensitivity MR analyses evaluating the effect of genetically-determined LDL cholesterol on risk of 




Acronyms: MR: Mendelian Randomization; LDL: low-density lipoprotein; GLGC: Global Lipids Genetics Consortium; 
UK: United Kingdom. 
 
* Neurology. 2019 Mar 12;92(11):e1176-e1187. ** Stroke. 2018 Apr;49(4):820-827.  
Ischemic stroke 
subtype 
Lipid estimates from the GLGC 
2019 Valdes-Marquez et al* 
Lipid estimates from the GLGC 
2018 Hindy et al** 
Lipid estimates from the 
UK Biobank (this study) 
Cardioembolic 1.06 (0.84 - 1.33) 0.99 (0.84 - 1.16) 1.05 (0.97 -1.13) 
Large artery 1.10 (0.82 - 1.47) 1.28 (1.07 - 1.53) 1.37 (1.24 - 1.51) 
Small vessel 1.14 (0.88 - 1.48) 1.09 (0.93 - 1.28) 1.12 (1.03 - 1.22) 
This article is protected by copyright. All rights reserved.
 
 
Acronyms: ICH: Intracerebral hemorrhage; PRS: polygenic risk score; OR: odds ratio; CI: confidence intervals; LDL: low-density 
lipoprotein.  
 
* Inverse variance fixed effects metanalysis of logistic regression results for ICH across GOCHA, ISGC ICH GWAS and GERFHS. 
For each study, the logistic regression model used ICH risk as the dependent variable and a polygenic risk score as the 
independent variable, adjusting for age, sex and 4 principal components. The PRS were normalized and entered to the model as 
a continuous predictor. The OR represents the change in the odds of ICH per each additional standard deviation of the PRS. 
 
** Mendelian randomization results of genetically instrumented cholesterol levels using a polygenic risk score as the instrument. 
Each lipid fraction-specific analysis utilized the ratio method, taking the effect estimates for ICH ~ PRS (numerator) and lipid level 
~ PRS (denominator). 
 
Table 7: Location-specific results for ICH risk.  
Lipid trait 
 Lobar ICH  
 n = 539 cases 
 Nonlobar ICH 
 n = 704 cases 
OR (95%CI) P Metanalysis Heterogeneity P OR (95%CI) P 
Metanalysis 
Heterogeneity P 
Polygenic risk score analysis * 
Total cholesterol 0.89 (0.80 - 0.99) 0.03 0.42 0.94 (0.85 - 1.08) 0.20 0.96 
LDL cholesterol 0.81 (0.73 - 0.89) <0.001 0.96 0.90 (0.82 - 0.99) 0.04 0.99 
       
Mendelian randomization analysis ** 
Total cholesterol 0.70 (0.51 - 0.96) 0.03 - 0.73 (0.62 - 1.11) 0.20 - 
LDL cholesterol 0.41 (0.27 - 0.64) <0.001 - 0.66 (0.44 - 0.97) 0.04 - 
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Acronyms: UK: United Kingdom; GOCHA: Genetics of Cerebral Hemorrhage with Anticoagulation; ISGC: International Stroke 
Genetics Consortium; GERFHS: Genetic and Environmental Risk Factors for Hemorrhagic Stroke; ICH: intracerebral hemorrhage; 
PRS: polygenic risk score; SNPs (single nucleotide polymorphisms); SD: standard deviation. 
 
Table 1. Studies included in this analysis. 
Characteristic UK Biobank GOCHA ISGC ICH Study GERFHS 
Analytical stage Association Cholesterol level ~ PRS 
Association 
ICH Risk ~ PRS 
Association 
ICH Risk ~ PRS 
Association 
ICH Risk ~ PRS 
Study design Cohort Case / Control Case / Control Case / Control 
Study participants 316,428 277 / 248 563 / 523 446 / 490 
Age, mean (SD) 68 (8) 73 (10) / 72 (8) 71 (14) / 66 (16) 70 (14) / 68 (13) 
Female sex n, % 170,871 (54) 130 (47) / 123 (50) 252 (45) / 255 (49) 211 (47) / 235 (48) 




HumanHap550 Affymetrix 6.0 
Genotyped SNPs 820,967 527,508 527,508 580,491 
Imputed SNPs 73,355,667 7,965,700 7,965,700 7,967,430 
This article is protected by copyright. All rights reserved.
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Table 2. Association results for 4 PRS with their corresponding trait in the UK Biobank. 
Lipid Trait PRS Independent SNPS in PRS 
UK Biobank  
Effective  
sample size 
Mean increase in  
cholesterol trait per 





      
Total Cholesterol 410 316,428 0.33 mmol/L (12.76 mg/dL) 0.0018 9.33% <1x10-100 
LDL Cholesterol 339 315,841 0.24 mmol/L (9.28 mg/dL) 0.0014 8.38% <1x10-100 
HDL Cholesterol 393 289,349 0.11 mmol/L (4.25 mg/dL) 0.0006 8.17% <1x10-100 
Triglycerides 317 316,174 0.22 mmol/L (19.49 mg/dL) 0.0017 4.8% <1x10-100 
      
Total Cholesterol 410 437,676 0.26 mmol/L (10.05 mg/dL) 0.0017 5.21% <1x10-100 
LDL Cholesterol 339 436,867 0.19 mmol/L (7.35 mg/dL) 0.0013 4.72% <1x10-100 
HDL Cholesterol 393 400,579 0.11 mmol/L (4.25 mg/dL) 0.0005 8.04% <1x10-100 
Triglycerides 317 437,331 0.23 mmol/L (20.37 mg/dL) 0.0015 5% <1x10-100 
 
Acronyms: PRS: polygenic risk score; UK: United Kingdom; SNP: single nucleotide polymorphism; LDL: low-density lipoprotein; HDL: High-density lipoprotein. Conversion 
of mmol/L to mg/dL: for TC, LDL and HDL 1 mmol/L = 38.67 mg/dL; for triglycerides, 1 mmol/L = 88.57 mg/dL. 
 
* The primary analysis was restricted to unrelated study participant of genetically-determined European ancestry who were not taking lipid-lowering medications. 
 
** The secondary analysis included all study participants of self-reported European ancestry without any other filters. 
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Acronyms: ICH: intracerebral hemorrhage; PRS (polygenic risk score); LDL: low-density lipoprotein; HDL: high-density lipoprotein; CI: 
confidence interval; GOCHA: Genetics of Cerebral Hemorrhage with Anticoagulation; ISGC: International Stroke Genetics Consortium; 
GERFHS: Genetic and Environmental Risk Factors for Hemorrhagic Stroke; FE: Fixed-Effects. RE: Random effects. Het-p: heterogeneity-
p for the metanalysis. 
Table 3: Study-specific and metanalysis of logistic regression results modeling ICH risk as a function of different PRS.  
Study 
Total Cholesterol LDL Cholesterol HDL Cholesterol Triglycerides 
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P  
GOCHA 0.95 (0.80 - 1.14) 0.59 0.93 (0.78 - 1.11) 0.41 1.12 (0.94 - 1.34) 0.20 0.95 (0.80 - 1.14) 0.59 
ISGC ICH  0.93 (0.82 - 1.05) 0.24 0.88 (0.77 - 0.99) 0.04 1.15 (1.01 - 1.30) 0.03 1.01 (0.89 - 1.14) 0.84 
GERFHS 0.88 (0.77 - 1.01) 0.07 0.85 (0.75 - 0.97) 0.02 0.99 (0.86 - 1.12) 0.84 1.19 (1.04 - 1.36) 0.009 
Fixed effects  
Meta-analysis 0.92 (0.85 - 0.99) 
0.03  
 0.88 (0.81 - 0.95) 
0.002 
 1.10 (1.00 - 1.21) 
0.06  




Meta-analysis 0.92 (0.84 - 0.99) 0.03 0.88 (0.81 - 0.95) 0.002 1.08 (0.98 - 1.19) 0.13 1.05 (0.93 – 1.20) 0.42 
Heterogeneity I2=0% 0.77 I2=0%  0.75 I2=32% 0.23 I2=60% 0.08 
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Table 4: Metanalysis of logistic regression results modeling ICH risk as a function of different PRS, excluding 
CETP variants. 
 
Lipid PRS OR (95% CI) P 
Total Cholesterol 0.91 (0·84 - 0·99) 0.03 
LDL Cholesterol 0.88 (0·81 - 0·96) 0.003 
HDL Cholesterol 1.12 (0·99 - 1·21) 0.08 
Triglycerides 1.11 (0·98 - 1·23) 0.12 
 
Acronyms: ICH: intracerebral hemorrhage; PRS (polygenic risk score); CI: confidence interval; LDL: low-
density lipoprotein; HDL: high-density lipoprotein. 
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Table 5: Mendelian randomization analysis of genetically instrumented lipid levels and risk of ICH. 
 
 
Acronyms: ICH: intracerebral hemorrhage; LDL: low-density lipoprotein; OR: odds ratio; CI: confidence interval; SNPs: single 






Total Cholesterol LDL Cholesterol 
OR (95%CI) P OR (95%CI) P 
Ratio method Polygenic risk score 
using on individual level data 0.77 (0.6 - 0.98) 0.03 0.59 (0.42 - 0.82) 0.002 
IVW Multiple SNPs 
using summary level data 0.84 (0.72 - 0.99) 0.04 0.65 (0.52 - 0.82) <0.001 
Weighted median Multiple SNPs 








using summary level data 1.00 (0.99 - 1.01) 0.81 1.00 (0.98 - 1.01) 0.59 
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Table 6. Sensitivity MR analyses evaluating the effect of genetically-determined LDL cholesterol on risk of 




Acronyms: MR: Mendelian Randomization; LDL: low-density lipoprotein; GLGC: Global Lipids Genetics Consortium; 
UK: United Kingdom. 
 
* Neurology. 2019 Mar 12;92(11):e1176-e1187. ** Stroke. 2018 Apr;49(4):820-827.  
Ischemic stroke 
subtype 
Lipid estimates from the GLGC 
2019 Valdes-Marquez et al* 
Lipid estimates from the GLGC 
2018 Hindy et al** 
Lipid estimates from the 
UK Biobank (this study) 
Cardioembolic 1.06 (0.84 - 1.33) 0.99 (0.84 - 1.16) 1.05 (0.97 -1.13) 
Large artery 1.10 (0.82 - 1.47) 1.28 (1.07 - 1.53) 1.37 (1.24 - 1.51) 
Small vessel 1.14 (0.88 - 1.48) 1.09 (0.93 - 1.28) 1.12 (1.03 - 1.22) 
This article is protected by copyright. All rights reserved.
 
 
Acronyms: ICH: Intracerebral hemorrhage; PRS: polygenic risk score; OR: odds ratio; CI: confidence intervals; LDL: low-density 
lipoprotein.  
 
* Inverse variance fixed effects metanalysis of logistic regression results for ICH across GOCHA, ISGC ICH GWAS and GERFHS. 
For each study, the logistic regression model used ICH risk as the dependent variable and a polygenic risk score as the 
independent variable, adjusting for age, sex and 4 principal components. The PRS were normalized and entered to the model as 
a continuous predictor. The OR represents the change in the odds of ICH per each additional standard deviation of the PRS. 
 
** Mendelian randomization results of genetically instrumented cholesterol levels using a polygenic risk score as the instrument. 
Each lipid fraction-specific analysis utilized the ratio method, taking the effect estimates for ICH ~ PRS (numerator) and lipid level 
~ PRS (denominator). 
 
Table 7: Location-specific results for ICH risk.  
Lipid trait 
 Lobar ICH  
 n = 539 cases 
 Nonlobar ICH 
 n = 704 cases 
OR (95%CI) P Metanalysis Heterogeneity P OR (95%CI) P 
Metanalysis 
Heterogeneity P 
Polygenic risk score analysis * 
Total cholesterol 0.89 (0.80 - 0.99) 0.03 0.42 0.94 (0.85 - 1.08) 0.20 0.96 
LDL cholesterol 0.81 (0.73 - 0.89) <0.001 0.96 0.90 (0.82 - 0.99) 0.04 0.99 
       
Mendelian randomization analysis ** 
Total cholesterol 0.70 (0.51 - 0.96) 0.03 - 0.73 (0.62 - 1.11) 0.20 - 
LDL cholesterol 0.41 (0.27 - 0.64) <0.001 - 0.66 (0.44 - 0.97) 0.04 - 
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